RJA
TXMD icon

Raymond James & Associates’s TherapeuticsMD TXMD Stock Holding History

Raymond James & Associates’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,455
Closed -$28K – 4221
2022
Q1 		$28K Sell
1,455
-292
-17% -$4.59K ﹤0.01% 3968
2021
Q4 		$31K Sell
1,747
-1,863
-52% -$55.8K ﹤0.01% 3992
2021
Q3 		$134K Sell
3,610
-6,536
-64% -$290K ﹤0.01% 3770
2021
Q2 		$604K Sell
10,146
-351
-3% -$21.3K ﹤0.01% 2950
2021
Q1 		$703K Buy
10,497
+197
+2% +$15.4K ﹤0.01% 2756
2020
Q4 		$623K Sell
10,300
-486
-5% -$33.2K ﹤0.01% 2668
2020
Q3 		$852K Sell
10,786
-247
-2% -$19.7K ﹤0.01% 2277
2020
Q2 		$690K Sell
11,033
-2
-0% -$116 ﹤0.01% 2389
2020
Q1 		$585K Buy
11,035
+1,843
+20% +$183K ﹤0.01% 2312
2019
Q4 		$1.11M Sell
9,192
-3,977
-30% -$572K ﹤0.01% 2213
2019
Q3 		$2.39M Sell
13,169
-207
-2% -$29.2K ﹤0.01% 1668
2019
Q2 		$1.74M Sell
13,376
-1,233
-8% -$221K ﹤0.01% 1880
2019
Q1 		$3.56M Buy
14,609
+652
+5% +$173K 0.01% 1391
2018
Q4 		$2.66M Sell
13,957
-1,209
-8% -$295K ﹤0.01% 1470
2018
Q3 		$4.97M Buy
15,166
+775
+5% +$237K 0.01% 1221
2018
Q2 		$4.49M Buy
14,391
+3,326
+30% +$1.02M 0.01% 1257
2018
Q1 		$2.69M Buy
11,065
+654
+6% +$183K ﹤0.01% 1507
2017
Q4 		$3.14M Buy
10,411
+2,620
+34% +$729K 0.01% 1399
2017
Q3 		$2.06M Buy
7,791
+513
+7% +$148K ﹤0.01% 1626
2017
Q2 		$1.92M Buy
7,278
+1,615
+29% +$405K ﹤0.01% 1600
2017
Q1 		$2.04M Buy
5,663
+648
+13% +$201K ﹤0.01% 1516
2016
Q4 		$1.45M Sell
5,015
-204
-4% -$63.2K ﹤0.01% 1708
2016
Q3 		$1.78M Buy
5,219
+1,595
+44% +$583K ﹤0.01% 1531
2016
Q2 		$1.54M Buy
3,624
+3,072
+557% +$1.27M ﹤0.01% 1479
2016
Q1 		$177K Buy
552
+40
+8% +$13.6K ﹤0.01% 2604
2015
Q4 		$265K Buy
+512
New +$189K ﹤0.01% 2239
2015
Q3 		– Sell
-758
Closed -$298K – 2385
2015
Q2 		$298K Buy
758
+43
+6% +$15.2K ﹤0.01% 2281
2015
Q1 		$216K Buy
+715
New +$175K ﹤0.01% 2307

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Raymond James & Associates's TXMD Position: Q2 2022 in Review

Raymond James & Associates sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 1,455 shares — an estimated $28K sold.

Raymond James & Associates first reported a position in TXMD in Q1 2015 and held it in 28 quarters. The position peaked at $4.97M in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Raymond James & Associates reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 1,455 TherapeuticsMD shares in Q2 2022, an estimated $28K.
  • Raymond James & Associates first reported a position in TherapeuticsMD in Q1 2015 and held it in 28 quarters.
  • Raymond James & Associates's TherapeuticsMD position peaked at $4.97M in Q3 2018.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.